Constellation begins Phase Ib/II PROSTAR trial of CPI-1205

Constellation Pharmaceuticals Inc. (Cambridge, Mass.) began the Phase Ib/II PROSTAR trial evaluating CPI-1205 plus Xtandi enzalutamide and CPI-1205 plus Zytiga abiraterone and prednisone to treat metastatic castration-resistant prostate cancer (mCRPC).

The Phase Ib portion will assess safety, pharmacokinetics and the recommended Phase II dose. The Phase II portion will evaluate clinical activity and potential biomarkers of response to the candidate...